+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID07092202

Study of High-Dose Firmonertinib With Intrathecal Pemetrexed for EGFR Mutant NSCLC Patients With Leptomeningeal Metastases Monitoring Treatment Using cfDNA in Cerebrospinal Fluid

Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2025-07-29

40

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Leptomeningeal metastases LM are a rare but serious form of spread in advanced non-small cell lung cancer NSCLC, often linked to EGFR mutations and associated with a poor outlook. Researchers aim to evaluate whether high-dose Firmonertinib combined with intrathecal chemotherapy can improve treatment outcomes for patients with EGFR mutant NSCLC who develop LM. This study also explores the potential of cerebrospinal fluid CSF circulating free DNA cfDNA as a biomarker to monitor treatment response in LM, addressing the current lack of effective monitoring tools. Participants will receive Firmonertinib at 160 mg orally once daily along with intrathecal injections of pemetrexed. The dosage of pemetrexed depends on body weight for those above 50 kg, an induction phase with 40 mg on days 1 and 5 every 3 weeks for 4 cycles followed by consolidation with 40 mg every 4 weeks until CSF ctDNA is negative for those below 50 kg, similar schedules apply with 30 mg doses. This prospective, multicenter, single-arm trial assesses the safety and efficacy of this combined high-dose targeted and local chemotherapy approach. During the study, participants will undergo dynamic monitoring of cfDNA levels in both cerebrospinal fluid and peripheral blood to evaluate treatment effects and safety. The primary outcome is progression-free survival over 2 years. Patients will have regular assessments including laboratory tests and lumbar punctures for CSF collection, and their physical condition will be monitored to ensure adherence and manage side effects. The study spans from April 2025 to November 2027, providing comprehensive follow-up for efficacy and biomarker validation.

CONDITIONS

Brief Title

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

Research Team

P

Peng Ding, Dr

X

Xiaorong Dong, Dr

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here